graph Evidence gap map comparisons
abemaciclib based treatmentcyclin inhibitorpalbociclib based treatmentribociclib based treatment
abemaciclib plus fulvestrant dalpiciclib plus fulvestrant palbociclib plus fulvestrant ribociclib plus endocrine therapy ribociclib plus fulvestrant
la/mBC - HR-positive - 2nd line (L2) 20            
la/mBC - HR positive - L2 - all population 1
la/mBC - HR positive - L2 - PIK3CA mutant 1
Comparator:  vs fulvestrant;   vs endocrine therapy; 
Risk of bias:  low;   some concerns;   high;  NA;